We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Nesiritide during extracorporeal membrane oxygenation.
- Authors
Smith, Todd; Rosen, David A.; Russo, Pierantonio; Berkenbosch, John W.; Gustafson, Robert A.; Siu, Benjamin L.; Rosen, Kathleen R.; Tobias, Joseph D.
- Abstract
Nesiritide is a recombinant formulation of B-type natriuretic peptide (BNP). Preliminary experience in the adult population has shown nesiritide to be an effective agent in the treatment of decompensated congestive heart failure (CHF) in adults. Given its physiological effects, it may be an effective agent in other clinical scenarios. We report the use of nesiritide in two infants during extracorporeal membrane oxygenation (ECMO). In one patient, nesiritide in doses up to 0.09 μg·kg−1·min−1 were used to control mean arterial pressure while in the other patient, doses of 0.01–0.03 μg·kg−1·min−1 were used to augment urine output. The potential applications of nesiritide and dosingregimens for this agent in the ECMO population are discussed.
- Subjects
CONGESTIVE heart failure; ATRIAL natriuretic peptides; EXTRACORPOREAL membrane oxygenation; ARTIFICIAL blood circulation; CARDIAC arrest; CLINICAL medicine
- Publication
Pediatric Anesthesia, 2005, Vol 15, Issue 2, p152
- ISSN
1155-5645
- Publication type
Article
- DOI
10.1111/j.1460-9592.2004.01398.x